Myelofibrosis Secondary to PV and ET Prognostic Model

A prognostic tool (MYSEC‑PM) that predicts survival in post‑polycythemia vera and post‑essential thrombocythemia myelofibrosis.

Hemoglobin
≥ 11 g/dL0< 11 g/dL+2
Platelets
≥ 150×10⁹ /L0< 150×10⁹ /L+1
Circulating blast cells
< 3%0≥ 3%+2
CALR-unmutated genotype
No0Yes+2
Constitutional symptoms
No0Yes+1
years

Indications for Use

Used to risk‑stratify patients with post‑PV or post‑ET myelofibrosis to estimate survival and guide intensity of therapy, particularly timing of allogeneic transplant. Incorporates age, symptoms, Hb, platelets, blasts, CALR status, and other molecular/cytogenetic factors, providing survival‑discriminatory categories validated for secondary MF and recommended for clinical and trial decision‑making 1 [Level III evidence]; 2 [Level II evidence].

Insights & Cautions

Assigns risk using age, symptoms, hemoglobin, circulating blasts, platelet count, and CALR‑mutation status to predict survival in post‑PV/ET MF; higher age, anemia, blasts, thrombocytopenia, and CALR‑unmutated genotype drive worse outcomes 1 [Level II evidence]. Use cautiously: underestimates impact of adverse mutations (ASXL1, SRSF2, TP53) highlighted in broader MF cohorts 2 [Level II evidence], and may misclassify patients with high‑risk cytogenetics.